Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Amerikaanse aandelen  /  HOT stocks vandaag.

Ontvang nu dagelijks onze kooptips!

word abonnee

Amerikaanse aandelen« Terug naar discussie overzicht

HOT stocks vandaag.

12.177 Posts
Pagina: «« 1 ... 600 601 602 603 604 ... 609 »» | Laatste | Omlaag ↓
  19. StephanO 15 maart 2015 21:14
    LLBO is ook uit de startblokken geschoten. Nog steeds is er enorm rendement te behalen. 2015 wordt een belangrijk jaar voor LLBO. Vond het volgende artikel op CNN money. Aandeel noteert nu 0,004

    The Company (OTC PINK: LLBO) (PINKSHEETS: LLBO) updates the meaningful activities for First Quarter of 2015:
    In 2008 Lifeline Biotechnologies exclusively licensed its First Warning Systems technology to First Warning Systems, Inc., (now called Cyrcadia Health) via a revenue royalty license of its patented, circadian rhythm based, pattern recognition technology. Three rounds of proof of concept trials were conducted and validated by the foremost pattern recognition engineers in the world (the Engineers at Nanyang Technological University in Singapore).
    LLBO's primary asset is its investment in Cyrcadia Inc. (Cyrcadia). That investment is achieving meaningful added value as Cyrcadia prepares to enter the final clinical trials that will be conducted at El Camino Hospital (ECH) in Mountain View, CA and the Ohio State University (OSU) Oncology Hospital in Columbus, OH. The trials have been approved through Investigational Review Boards (IRB's) of ECH and are currently undergoing the review process at OSU. The ECH trial is slated for start before the end of April 2015. The trials are expected to be completed in four to 6 months. On completion Cyrcadia will obtain CE Marking allowing for sales and marketing outside of the USA. On completion of the trials Cyrcadia will be submitting a 510(k) to the FDA. Post clearance, marketing will begin in the USA. International sales are expected in Q4 of 2015 and US sales in Q1 or Q2 of 2016.
    It is interesting to note that Dr. Farrar at OSU will be the primary investigator for the trials conducted at OSU. Dr. Farrar headed the original "proof of concept" study that was conducted at OSU. Dr. Farrar published on the results of this study, commenting on the potential of this lifesaving technology that could assist in the early detection of breast tissue abnormalities and breast cancers. A copy of Dr. Farrar's abstract will be posted on the Lifeline website in the next few days.
    Other developments:
    Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.

    money.cnn.com/news/newsfeeds/articles...

    Verder vond ik vandaag het volgende:

    LIFELINE BIOTECH (OTCMKTS:LLBO) is making a spectacular move up on massive volume in recent days. Over the past few months LLBO has transformed from illiquid at $0.0001 to one of the top traded stocks on the entire bb.

    LLBO move up is marked by steady accumulation and excellent support as the stock explode in sub penny land recently topping 100 million shares traded in daily trading volume.

    LIFELINE BIOTECH (OTCMKTS:LLBO) was founded in 1994 and is based in Reno, NV. The Company has invested over $10M in a device and process for early detection of breast tissue abnormalities some of which are cancerous or pre-cancer. Three “Proof of Concept” clinical trials of over 500 women have been completed and three patents (one hardware, two software) have been awarded.

    LLBO owns 40% of Cyrcadia Health who’s product line is a device and software service that detects breast tissue abnormalities leading to health risk assessment and management including early breast cancer identification. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. Cyrcadia Health technology is exclusively licensed for development, manufacturing and marketing worldwide from Lifeline Biotechnologies, Inc (OTC Market: LLBO).

    Cyrcadia Health is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. Cyrcadia Health is preparing to apply for a Euro CE Mark to market in the European Union and Asia Pacific markets.

    On March 12 LLBO updates the meaningful activities for First Quarter of 2015: In 2008 Lifeline Biotechnologies exclusively licensed its First Warning Systems technology to First Warning Systems, Inc., (now called Cyrcadia Health) via a revenue royalty license of its patented, circadian rhythm based, pattern recognition technology. Three rounds of proof of concept trials were conducted and validated by the foremost pattern recognition engineers in the world (the Engineers at Nanyang Technological University in Singapore).

    LLBO’s primary asset is its investment in Cyrcadia Inc. That investment is achieving meaningful added value as Cyrcadia prepares to enter the final clinical trials that will be conducted at El Camino Hospital (ECH) in Mountain View, CA and the Ohio State University (OSU) Oncology Hospital in Columbus, OH.

    The trials have been approved through Investigational Review Boards (IRB’s) of ECH and are currently undergoing the review process at OSU. The ECH trial is slated for start before the end of April 2015. The trials are expected to be completed in four to 6 months.

    On completion Cyrcadia will obtain CE Marking allowing for sales and marketing outside of the USA. On completion of the trials Cyrcadia will be submitting a 510(k) to the FDA. Post clearance, marketing will begin in the USA. International sales are expected in Q4 of 2015 and US sales in Q1 or Q2 of 2016.

    It is interesting to note that Dr. Farrar at OSU will be the primary investigator for the trials conducted at OSU. Dr. Farrar headed the original “proof of concept” study that was conducted at OSU. Dr. Farrar published on the results of this study, commenting on the potential of this lifesaving technology that could assist in the early detection of breast tissue abnormalities and breast cancers. A copy of Dr. Farrar’s abstract will be posted on the Lifeline website in the next few days.

    www.microcapdaily.com/stock-on-the-mo...

    Fijne avond
12.177 Posts
Pagina: «« 1 ... 600 601 602 603 604 ... 609 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 870,27 -0,43%
EUR/USD 1,0729 +0,30%
FTSE 100 8.078,86 +0,48%
Germany40^ 17.931,00 -0,87%
Gold spot 2.332,03 +0,69%
NY-Nasdaq Composite 15.611,76 -0,64%

Stijgers

UNILEV...
+5,85%
RENEWI
+4,68%
B&S Gr...
+2,85%
Flow T...
+2,26%
Fugro
+2,09%

Dalers

ADYEN NV
-18,43%
VIVORY...
-8,38%
WDP
-4,93%
Alfen ...
-4,39%
CM.COM
-3,66%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!